Torque teno virus: a potential marker of immune reconstitution in youths with vertically acquired HIV.
Humans
Torque teno virus
/ genetics
HIV Infections
/ immunology
Male
Female
Adolescent
Viral Load
Biomarkers
/ blood
Retrospective Studies
Child
Infectious Disease Transmission, Vertical
Immune Reconstitution
Young Adult
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Adult
Antiretroviral treatment
CD4/CD8 ratio
Immune reconstitution
TTV
Youths with vertically acquired HIV
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
21
06
2024
accepted:
23
09
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
Torque teno virus (TTV) viral load (VL), a component of the human virome, increases during immune suppression or dysregulation. This study aimed to explore TTV VL in youths living with vertically acquired HIV (YWVH) and its potential as an immunovirological marker. We performed an observational, retrospective study involving YWVH under antiretroviral treatment (ART) from the Spanish Cohort of HIV-infected children, adolescents, and vertically HIV-infected patients transferred to Adult Units (CoRISpe-FARO), compared to HIV-negative healthy donors (HD). Plasma TTV VL was assessed by qPCR. T-cell phenotype was analysed on cryopreserved peripheral blood mononuclear cells by flow cytometry. Correlations with baseline CD4 and CD8 and long-term virological evolution were examined. A total of 57 YWVH were compared with 23 HD. YWVH had a median CD4 T-cells of 736 cells/mm
Identifiants
pubmed: 39433755
doi: 10.1038/s41598-024-73870-2
pii: 10.1038/s41598-024-73870-2
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
24691Subventions
Organisme : Centro de Investigación Biomédica en Red de Enfermedades Infecciosas-ISCIII (CIBERINFEC)
ID : CB21/13/00025
Organisme : Centro de Investigación Biomédica en Red de Enfermedades Infecciosas-ISCIII (CIBERINFEC)
ID : CB21/13/00077
Organisme : Centro de Investigación Biomédica en Red de Enfermedades Infecciosas-ISCIII (CIBERINFEC)
ID : CB21/13/00044
Organisme : Instituto de Salud Carlos III (ISCIII). Miguel Servet Program
ID : CP23/00009
Organisme : Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
ID : CB22/01/00041
Informations de copyright
© 2024. The Author(s).
Références
Focosi, D., Antonelli, G., Pistello, M. & Maggi, F. Torquetenovirus: The human virome from bench to bedside. Clin. Microbiol. Infect. 22, 589–593 (2016).
pubmed: 27093875
doi: 10.1016/j.cmi.2016.04.007
De Vlaminck, I. et al. Temporal response of the human virome to Immunosuppression and antiviral therapy. Cell 155, 1178–1187 (2013).
pubmed: 24267896
pmcid: 4098717
doi: 10.1016/j.cell.2013.10.034
Fogli, M. et al. Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance. Clin. Dev. Immunol. 1–10 (2012). (2012).
Solis, M. et al. Torquetenovirus viremia for early prediction of graft rejection after kidney transplantation. J. Infect. 79, 56–60 (2019).
pubmed: 31100359
doi: 10.1016/j.jinf.2019.05.010
Sawata, T. et al. Clinical significance of changes in Torque Teno virus DNA titer after chemotherapy in patients with primary lung cancer. Respir Investig. 56, 173–178 (2018).
pubmed: 29548656
doi: 10.1016/j.resinv.2017.12.004
Mallet, F. et al. Early herpes and TTV DNAemia in septic shock patients: A pilot study. Intens Care Med. Exp. 7, 28 (2019).
doi: 10.1186/s40635-019-0256-z
Focosi, D., Macera, L., Boggi, U., Nelli, L. & Maggi, F. Short-term kinetics of torque teno virus viraemia after induction immunosuppression confirm T lymphocytes as the main replication-competent cells. J. Gen. Virol. 96, 115–117 (2015).
pubmed: 25304651
doi: 10.1099/vir.0.070094-0
Albert, E. et al. Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. Med. Microbiol. Immunol. 208, 253–258 (2019).
pubmed: 30852649
doi: 10.1007/s00430-019-00586-w
Focosi, D. et al. Torquetenovirus viremia kinetics after autologous stem cell transplantation are predictable and may serve as a surrogate marker of functional immune reconstitution. J. Clin. Virol. 47, 189–192 (2010).
pubmed: 20034850
doi: 10.1016/j.jcv.2009.11.027
Albert, E. et al. The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transpl. 53, 180–187 (2018).
doi: 10.1038/bmt.2017.235
Elesinnla, A., Adeleye, I., Ayolabi, C. & Bessong, P. Prevalence of torque viruses in HIV-infected and non-HIV-infected Nigerian subjects: Analysis of near-full-length genome sequences. Arch. Virol. 165, 571–582 (2020).
pubmed: 32030535
doi: 10.1007/s00705-020-04538-1
Shibayama, T. et al. Inverse relationship between the titre of TT virus DNA and the CD4 cell count in patients infected with HIV. AIDS 15, 563–570 (2001).
pubmed: 11316992
doi: 10.1097/00002030-200103300-00004
Thom, K. & Petrik, J. Progression towards AIDS leads to increased torque teno virus and torque teno minivirus titers in tissues of HIV infected individuals. J. Med. Virol. 79, 1–7 (2007).
pubmed: 17133553
doi: 10.1002/jmv.20756
Lapa, D. et al. Clinical relevance of Torque Teno Virus (TTV) in HIV/HCV coinfected and HCV Monoinfected patients treated with direct-acting antiviral therapy. J. Clin. Med. 10, 2092 (2021).
pubmed: 34068071
pmcid: 8152458
doi: 10.3390/jcm10102092
Honorato, L. et al. The Torque Teno Virus Titer in Saliva reflects the level of circulating CD4+ T lymphocytes and HIV in individuals undergoing antiretroviral maintenance therapy. Front. Med. 8, 809312 (2022).
doi: 10.3389/fmed.2021.809312
Schmidt, L. et al. Torque Teno Virus plasma level as novel biomarker of retained immunocompetence in HIV-infected patients. Infection. 49, 501–509 (2021).
pubmed: 33537915
pmcid: 8159784
doi: 10.1007/s15010-020-01573-7
Carrasco, I. et al. Innate and adaptive abnormalities in youth with vertically acquired HIV through a multicentre cohort in Spain. J. Int. AIDS Soc. 24, e25804 (2021).
pubmed: 34672108
pmcid: 8528666
doi: 10.1002/jia2.25804
Sainz, T. et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS 27, 1513–1516 (2013).
pubmed: 23435292
doi: 10.1097/QAD.0b013e32835faa72
Sudjaritruk, T. et al. Incidence of postsuppression virologic rebound in perinatally HIV-infected Asian adolescents on stable combination antiretroviral therapy. J. Adolesc. Health 61, 91–98 (2017).
pubmed: 28343759
pmcid: 5483211
doi: 10.1016/j.jadohealth.2017.01.014
Tarancon-Diez, L. et al. miRNA profile based on ART delay in vertically infected HIV-1 youths is associated with inflammatory biomarkers and activation and maturation immune levels. Front. Immunol. 13, 878630 (2022).
pubmed: 35529880
pmcid: 9074828
doi: 10.3389/fimmu.2022.878630
Tarancón-Diez, L. et al. Early antiretroviral therapy initiation effect on metabolic profile in vertically HIV-1-infected children. J. Antimicrob. Chemother. 76, 2993–3001 (2021).
pubmed: 34463735
doi: 10.1093/jac/dkab277
Deeks, S. & Phillips, A. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 338, a3172–a3172 (2009).
pubmed: 19171560
doi: 10.1136/bmj.a3172
Nasser, T. et al. Detection of TT virus in HIV-1 exposed but uninfected individuals and in HIV-1 infected patients and its influence on CD4 + lymphocytes and viral load. Microb. Pathog. 47, 33–37 (2009).
pubmed: 19409976
doi: 10.1016/j.micpath.2009.04.010
Westman, G., Schoofs, C., Ingelsson, M., Järhult, J. & Muradrasoli, S. Torque Teno virus viral load is related to age, CMV infection and HLA type but not to Alzheimer’s disease. PLoS ONE 15, e0227670 (2020).
pubmed: 31917803
pmcid: 6952092
doi: 10.1371/journal.pone.0227670
Tyschik, E., Rasskazova, A., Degtyareva, A., Rebrikov, D. & Sukhikh, G. Torque Teno virus dynamics during the first year of life. Virol. J. 15, 96 (2018).
pubmed: 29843750
pmcid: 5975406
doi: 10.1186/s12985-018-1007-6
Haloschan, M. et al. TTV DNA plasma load and its association with age, gender, and HCMV IgG serostatus in healthy adults. Age 36, 9716 (2014).
pubmed: 25284090
pmcid: 4185385
doi: 10.1007/s11357-014-9716-2
Chamekh, M. et al. Differential susceptibility to infectious respiratory diseases between males and females linked to sex-specific innate immune inflammatory response. Front. Immunol. 8, 1806 (2017).
pubmed: 29321783
pmcid: 5733536
doi: 10.3389/fimmu.2017.01806
Marriott, I. & Huet-Hudson, Y. Sexual dimorphism in innate immune responses to infectious organisms. Immunol. Res. 34, 177–192 (2006).
pubmed: 16891670
doi: 10.1385/IR:34:3:177
Sakiani, S., Olsen, N. & Kovacs, W. Gonadal steroids and humoral immunity. Nat. Rev. Endocrinol. 9, 56–62 (2013).
pubmed: 23183675
doi: 10.1038/nrendo.2012.206
Fischer, J. et al. Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. Gut 66, 1829–1837 (2017).
pubmed: 27196570
doi: 10.1136/gutjnl-2015-310239
Formiga, F. et al. Differences according to gender and health status in CD4:CD8 ratio in a sample of community-dwelling oldest old. The OCTABAIX immune study. Aging Clin. Exp. Res. 23, 268–272 (2011).
pubmed: 22067371
doi: 10.1007/BF03324966
Andrade-Santos, J. L., Carvalho-Silva, W. H. V., Souto, F. O., Crovella, S. & Guimarães, R. L. Differences in pyroptosis of recent thymic emigrants CD4 + T lymphocytes in ART-treated HIV-positive patients are influenced by sex. Immunogenetics. 73, 349–353 (2021).
pubmed: 33449124
doi: 10.1007/s00251-020-01202-5
Tarancon-Diez, L. et al. Transient viral rebound in children with perinatally acquired HIV-1 induces a unique soluble immunometabolic signature associated with decreased CD4/CD8 ratio. J. Pediatr. Infect. Dis. Soc. 12, 143–151 (2023).
doi: 10.1093/jpids/piad008
Serrano-Villar, S. et al. HIV-Infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8 + T cell activation, and increased risk of Non-AIDS morbidity and mortality. PLoS Pathog. 10, e1004078 (2014).
pubmed: 24831517
pmcid: 4022662
doi: 10.1371/journal.ppat.1004078
Maggi, F. et al. Changes in CD8 + 57 + T lymphocyte expansions after autologous hematopoietic stem cell transplantation correlate with changes in Torquetenovirus Viremia. Transplantation 85, 1867–1868 (2008).
pubmed: 18580484
doi: 10.1097/TP.0b013e31817615e6
Borges, Á. et al. Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-Reactive protein or D-Dimer during HIV infection. J. Infect. Dis. 214, 408–416 (2016).
pubmed: 27132283
pmcid: 4936649
doi: 10.1093/infdis/jiw173
Rocchi, J. et al. Torquetenovirus DNA drives proinflammatory cytokines production and secretion by immune cells via toll-like receptor 9. Virology 394, 235–242 (2009).
pubmed: 19765789
doi: 10.1016/j.virol.2009.08.036
Dominguez-Molina, B. et al. Toll-like receptor 7 (TLR-7) and TLR-9 agonists improve hepatitis C virus replication and infectivity inhibition by plasmacytoid dendritic cells. J. Virol. 92, 11 (2018).
doi: 10.1128/JVI.01219-18
Chris, D. TTV viral load as a marker for Immune reconstitution after initiation of HAART in HIV-Infected patients. HIV Clin. Trial. 3, 287–295 (2002).
doi: 10.1310/8C94-VYPQ-NG1H-4CNW
Leijonhufvud, G. et al. Better detection of Torque Teno virus in children with leukemia by metagenomic sequencing than by quantitative PCR. J. Med. Virol. 94, 634–641 (2022).
pubmed: 34672369
doi: 10.1002/jmv.27409
Focosi, D. et al. Assessment of prevalence and load of torquetenovirus viraemia in a large cohort of healthy blood donors. Clin. Microbiol. Infect. 26, 1406–1410 (2020).
pubmed: 31972321
doi: 10.1016/j.cmi.2020.01.011
Aguilera-Alonso, D. et al. Clinical, immunological, and virological outcomes among youths with Perinatal HIV after transition to adult units in Spain from 1997 to 2016. J. Acquir. Immune Defic. Syndr. 86, 240–247 (2021).
pubmed: 33074855
doi: 10.1097/QAI.0000000000002539